France
Kejako is a Swiss-based company with a mission to address presbyopia by merging Medtech and Engineering expertise to develop solutions for interested presbyopic patients seeking to maintain their quality of life through the compensation of visual accommodation decay. Unlike any other existing surgical solution, Kejako promises to provide a non-invasive (ultra-minimally invasive or a “no-cut”) laser solution to delay the need for reading glasses without compromising the patient’s quality of vision. Their solution is fully personalized to the patient using their simulation expertise, which is recognized by peers and utilized in providing simulation services to strategic partners. Kejako has the potential to become the next generation standard of care in personalized ophthalmic anti-aging medicine.
Founded in 2015, Kejako operates in the Biotechnology, Health Care, Health and Wellness, Medical Devices industries. The company, based in Switzerland and Saint-Étienne, received a Fr.750.00K Seed Round investment on 01 August 2022 from Business Angels Switzerland (BAS).
